Tumor-Infiltrating Lymphocytes (TILs)

Tumor-Infiltrating Lymphocytes (TILs)



Tumor-infiltrating lymphocytes (TILs) are lymphocytes located around tumor cells. TILs have been identified in primary tumors, lymph nodes, and metastases. TILs have dual roles on tumor progression.

The anti-tumor immune responses involve cytotoxic T lymphocytes (CTLs) and NK cells for killing tumor cells, Th1 cells for enhancing cytotoxic effects of killer cells, and M1 tumor-associated macrophages (TAMs) for signaling and promoting inflammation and anti-tumor responses. On the other hand, the pro-cancer immune responses involves regulatory T cells (Tregs) for suppressing CTLs, and Th2 cells for suppression of killer cells and inducing differentiation of M2 TAMs which in turn promote tumor growth via secretion of growth factors.

Tumor-infiltrating lymphocytes (TILs) are not only a powerful prognostic marker but also a potential key breakthrough for anti-tumor therapy. arigo offers excellent antibodies to facilitate the pathological studies of TILs.
 

T-cell infiltration
CD3 antibody [CD3-12]
(ARG22819)
CD4 antibody [SQab1714]
(ARG65860)
FoxP3 antibody
(ARG53050)
 
B-cell infiltration
CD19 antibody
(ARG52706)
CD20 antibody [L26]
(ARG56003)
CD79a antibody [SQab1743]
(ARG66254)
 
NK-cell infiltration
CD16 antibody [DJ130c]
(ARG23012)
CD56 antibody [123C3.D5]
(ARG55890)
CD56 antibody
(ARG55712)
 
Tumor-associated macrophages (TAMs)
CD68 antibody [KP1]
(ARG10514)
CD206 antibody
(ARG22372)
iNOS antibody
(ARG53372)